Additionally, our study demonstrated that knocking down IKZF3 in HER2-specific chimeric antigen receptor T cells, which target breast cancer cells, resulted in the enhanced killing of cancer cells in both in vitro and xenograft models. This evidence concerns the gene ERBB2 and breast carcinoma.